Neuberger Berman Group
ACRS icon

Neuberger Berman Group’s Aclaris Therapeutics ACRS Stock Holding History

Neuberger Berman Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.7K Buy
22,062
+3,107
+16% +$10.5K ﹤0.01% 2091
2025
Q4 		$57.1K Buy
18,955
+6,251
+49% +$15.8K ﹤0.01% 2047
2025
Q3 		$24.1K Buy
12,704
+48
+0.4% +$84 ﹤0.01% 2018
2025
Q2 		$18K Hold
12,656
– – ﹤0.01% 2027
2025
Q1 		$19.4K Hold
12,656
– – ﹤0.01% 1939
2024
Q4 		$31.4K Hold
12,656
– – ﹤0.01% 1898
2024
Q3 		$14.6K Hold
12,656
– – ﹤0.01% 1911
2024
Q2 		$13.9K Buy
12,656
+141
+1% +$166 ﹤0.01% 1885
2024
Q1 		$15.5K Sell
12,515
-5,704
-31% -$6.8K ﹤0.01% 1817
2023
Q4 		$19.1K Buy
+18,219
New +$55.6K ﹤0.01% 1835
2017
Q2 		– Sell
-40,000
Closed -$1.19M – 1587
2017
Q1 		$1.19M Buy
40,000
+27,000
+208% +$778K ﹤0.01% 1112
2016
Q4 		$353K Hold
13,000
– – ﹤0.01% 1375
2016
Q3 		$333K Buy
+13,000
New +$276K ﹤0.01% 1374

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Neuberger Berman Group's ACRS Position: Q1 2026 in Review

Neuberger Berman Group increased its Aclaris Therapeutics (ACRS) stake by 16% in Q1 2026, buying an estimated $10.5K and bringing the position to 22,062 shares worth $82.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Neuberger Berman Group first reported a position in ACRS in Q3 2016 and has held it in 13 quarters since. The position peaked at $1.19M in Q1 2017. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Neuberger Berman Group held 22,062 shares of Aclaris Therapeutics worth $82.7K as of Q1 2026.
  • Neuberger Berman Group bought 3,107 Aclaris Therapeutics shares in Q1 2026, an estimated $10.5K.
  • Aclaris Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #2091 holding.
  • Neuberger Berman Group first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 13 quarters since.
  • Neuberger Berman Group's Aclaris Therapeutics position peaked at $1.19M in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.